Psychotropic medications in children with autism spectrum disorders: A systematic review and synthesis for evidence-based practice

Journal of Autism and Developmental Disorders

Volumn 42, Issue 8, 2012, Pages 1592-1605

  Siegel, Matthew ^a   Beaulieu, Amy A ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN MAINE   (United States)

Author keywords

Autism; Evidence base; Pharmacology; Review; Trials

Indexed keywords

AMANTADINE; AMPHETAMINE; ARIPIPRAZOLE; ATOMOXETINE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; CLOZAPINE; CYPROHEPTADINE; DESIPRAMINE; DONEPEZIL; ETIRACETAM; FLUOXETINE; FLUVOXAMINE MALEATE; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; METHYLPHENIDATE; NALTREXONE; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; PENTOXIFYLLINE; PERPHENAZINE; PSYCHOTROPIC AGENT; RISPERIDONE; SERTRALINE; VALPROATE SEMISODIUM; ZIPRASIDONE;

AGGRESSION; ANOREXIA; APPETITE; ARTICLE; AUTISM; CHILDHOOD DISEASE; CONSTIPATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG RESPONSE; DRY SKIN; EMOTIONALITY; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERACTIVITY; HYPERSALIVATION; HYPOTENSION; IMPULSIVENESS; INSOMNIA; IRRITABILITY; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEREOTYPY; STOMACH CRAMP; STOMACH DISEASE; SYSTEMATIC REVIEW; TREMOR; TWITCHING MOTILITY; VOMITING; WEIGHT GAIN;

CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; EVIDENCE-BASED PRACTICE; HUMANS; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME;

EID: 84864343859     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-011-1399-2     Document Type: Article

References (47)

1. Akhondzadeh, S., Erfani, S., Mohammadi, M. R., Tehrani-Doost, M., Amini, H., Gudarzi, S. S., et al. (2004). Cyproheptadine in the treatment of autistic disorder: A double-blind placebo-controlled trial. Journal of Clinical Pharmacy & Therapeutics, 29(2), 145-150. (Pubitemid 38482479)
2. Akhondzadeh, S., Fallah, J., Mohammadi, M. R., Imani, R., Mohammadi, M., Salehi, B., et al. (2010). Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34, 32-36.
3. Aman, M. G., Singh, N. N., & Stewart, A. W. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiencies, 89, 485-491. (Pubitemid 15104762)
4. Aman, M. G., Lam, K. S., & Collier-Crespin, A. (2003). Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders, 33, 527-534. (Pubitemid 37351601)
5. Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 141(10), 195-202.
6. Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Developmental Disorders, 19(2), 227-239. (Pubitemid 19176531)
7. Arnold, L. E., Aman, M. G., Cook, A. M., Witwer, A. N., Hall, K. L., Thompson, S., et al. (2006). Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45(10), 1196-1205. (Pubitemid 44465640)
8. Beaulieu, A., Tweed, L., & Connolly, N. (2009). Interventions for autism spectrum disorders: State of the evidence. Augusta, Maine: Muskie School of Public Service and Maine Department of Health and Human Services.
9. Beduin, A. S., & de Haan, L. (2010). Off-label second generation antipsychotics for impulse regulation disorders: A review. Psychopharmacology Bulletin, 43(3), 45-81.
10. Belsito, L., Law, P., Kirk, K., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine therapy for autistic disorder: A randomized double-blind placebo-controlled trial. Journal of Autism and Developmental Disorders, 31(2), 175-181. (Pubitemid 37490163)
11. Campbell, M., Anderson, L. T., Small, A. M., Locascio, J. J., Lynch, N. S., & Choroco, M. C. (1990). Naltrexone in autistic children: A double-blind and placebo-controlled study. Psychopharmacology Bulletin, 26(1), 130-135. (Pubitemid 20322260)
12. Campbell, M., Anderson, L. T., Small, A. M., Adams, P., Gonzalez, N. M., & Ernst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry, 32(6), 1283-1291. (Pubitemid 23319191)
13. Chez, M. G., Buchanan, T. M., Becker, M., Kessler, J., Aimonovitch, M. C., & Mrazek, S. R. (2003). Donepezil hydrochloride: A double-blind study in autistic children. Journal of Pediatric Neurology, 1(2), 83-88.
14. Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., et al. (2003). Validation of a brief quantitative measure of autistic traits: Comparison of the Social Responsiveness Scale with the Autism Diagnostic Interview- Revised. Journal of Autism and Developmental Disorders, 33(4), 427-433. (Pubitemid 37127938)
15. Feldman, H. M., Kolmen, B. K., & Gonzaga, A. M. (1999). Naltrexone and communication skills in young children with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 38(5), 587-593. (Pubitemid 29203475)
16. Freeman, J. B., Choate-Summers, M. L., Garcia, A. M., Moore, P. S., Sapyta, J. J., Khanna, M. S., et al. (2009). The pediatric obsessive-compulsive disorder treatment study II: Rationale, design and methods. Child and Adolescent Psychiatry and Mental Health, 3(1), 4.
17. Gordon, C. T., State, R. C., Nelson, J. F., Hamburger, S. D., & Rapoport, J. L. (1993). A double-blind comparison of clomipramine, deipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441-447. (Pubitemid 23169937)
18. Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30(3), 245-255.
19. Handen, B., Sahl, R., & Harden, A. (2008). Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental and Behavioral Pediatrics, 29(4), 303-308.
20. Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., et al. (2005). A double-blind, placebocontrolled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15(4), 682-692. (Pubitemid 41434372)
21. Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., et al. (2005a). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology: Official Publication of The American College of Neuropsychopharmacology, 30(3), 582-589. (Pubitemid 40271160)
22. Hollander, E., Soorya, L., Wasserman, S., Esposito, K., Chaplin, W., & Anagnostou, E. (2005b). Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. The International Journal of Neuropsychopharmacology: Official Scientific Journal of The Collegium Internationale Neuropsychopharmacologicum (CINP), 9(2), 209-213. (Pubitemid 43255834)
23. Hollander, E., Wasserman, S., Swanson, E. N., Chaplin, W., Schapiro, M. L., Zagursky, K., et al. (2006). A double-blind placebocontrolled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child & Adolescent Psychopharmacology, 16, 541-548. (Pubitemid 44737209)
24. Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Russoff, J., et al. (2010). Divalproex sodium vs. placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 35(4), 990-998.
25. Jaselskis, C. A., Cook, E. H., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12(5), 322-327.
26. Johnson, C. P., & Myers, S. M. (2007). Identification and evaluation of children with autism spectrum disorders. Pediatrics, 120(5), 1183-1215. (Pubitemid 350085561)
27. King, B. H., & Bostic, J. Q. (2006). An update on pharmacologic treatments for autism spectrum disorders. Child and Adolescent Psychiatry Clinics of North America, 15(1), 161-175. (Pubitemid 41735242)
28. King, B. H., Wright, D. M., Handen, B. L., Sikich, L., Zimmerman, A. W., McMahon, W., et al. (2001). Double-blind placebocontrolled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 658-665. (Pubitemid 32473379)
29. King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahil, L., Bregman, J. D., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior. Archives of General Psychiatry, 66(6), 583-590.
30. Kolmen, B. K., Feldman, H. M., Handen, B. L., & Janosky, J. E. (1995). Naltrexone in young autistic children: A double-blind placebo-controlled crossover study. Journal of the American Academy of Child and Adolescent Psychiatry, 34(2), 223-231.
31. Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33, 159-174. (Pubitemid 8054849)
32. LeCavalier, L. (2006). Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders, 36, 1101-1114. (Pubitemid 46020362)
33. Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110-1119.
34. McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry, 162(6), 1142-1148. (Pubitemid 40770697)
35. Mcpheeters, M. L., Warren, Z., Sathe, N., et al. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127, e1312.
36. Miral, S., Gencer, O., Inal-Emiroglu, F. N., Baykara, B., Baykara, A., & Dirik, E. (2008). Risperidone versus haloperidol in children and adolescents with AD: A randomized, controlled, doubleblind trial. European Child and Adolescent Psychiatry, 17(1), 1-8.
37. Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533-1540.
38. Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., et al. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders, 25(3), 283-294.
39. Reichow, B., Volkmar, F. R., & Cicchetti, D. V. (2008). Development of the evaluative method for evaluating and determining evidence-based practices in autism. Journal of Autism and Developmental Disorders, 38, 1311-1319.
40. Remington, G., Sloman, L., Konstantareas, M., Parker, K., & Gow, R. (2001). Clomipramine versus haloperidol in the treatment of autistic disorder: A double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology, 4, 440-444. (Pubitemid 32673034)
41. Research Units on Pediatric Psychopharmacology Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314-321.
42. Research Units on Pediatric Psychopharmacology Autism Network. (2005). A randomized, double-blind, placebo-controlled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders. Archives of General Psychiatry, 62, 1266-1274.
43. Scahill, L., Riddle, M., & McSwiggin-Hardin, M. (1997). Children's yale-brown obsessive compulsive scale: Reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 844-852. (Pubitemid 27250450)
44. Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634-e641. (Pubitemid 41647671)
45. Wasserman, S., Iyengar, R., Chaplin, W. F., Watner, D., Waldoks, S. E., Anagnostou, E., et al. (2006). Levetiracetam versus placebo in childhood and adolescent autism: A double-blind placebocontrolled study. International Clinical Psychopharmacology, 21(6), 363-367. (Pubitemid 44498278)
46. Willemsen-Swinkels, S. H., Buitelaar, J. K., Weijnen, F. G., & van Engeland, H. (1995). Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Research, 58(3), 203-215.
47. Wong, H. H. L., & Smith, R. G. (2006). Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. Journal of Autism and Developmental Disorders, 36, 901-909. (Pubitemid 44440109)